Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
格莱沙替尼在携带 MET 外显子 14 突变的肺癌模型和患者中表现出抗肿瘤活性，并在非临床模型中克服了突变介导的对 I 型 MET 抑制剂的耐药性
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-17-1192
Lars D Engstrom, Ruth Aranda, Matthew Lee, Elizabeth A Tovar, Curt J Essenburg, Zachary Madaj, Harrah Chiang, David Briere, Jill Hallin, Pedro P Lopez-Casas, Natalia Baños, Camino Menendez, Manuel Hidalgo, Vanessa Tassell, Richard Chao, Darya I Chudova, Richard B Lanman, Peter Olson, Lyudmilla Bazhe
